Argentine Hemorrhagic Fever

Junin virus, the causative agent of Argentine Hemorrhagic Fever, is an Arenavirus with a bi-segmented RNA genome. The virus primarily targets endothelial cells, causing vascular damage and the characteristic hemorrhagic manifestations associated with the disease. The viral glycoprotein, responsible for mediating cell entry, is a key target for both natural immunity and vaccine development. Research efforts have focused on understanding the molecular interactions between Junin virus and host cells, providing insights into viral entry, replication, and immune evasion strategies. The development of a live-attenuated vaccine named Candid #1 has been a significant achievement in combating AHF. This vaccine, derived from the attenuated Candid #1 strain of Junin virus, has shown effectiveness in preventing severe forms of the disease and has been instrumental in vaccination campaigns in endemic areas. Ongoing research continues to explore new vaccine candidates, antiviral drugs, and therapeutic strategies for Argentine Hemorrhagic Fever, aiming to improve treatment outcomes and mitigate the impact of this potentially fatal disease on public health in affected regions.